Although there is strong evidence regarding the safety of CGRP mAbs in combination with “small molecule” drugs (e.g., antihypertensives, statins, antidiabetic agents, and antiseizure medications), no data are available about the safety of the combination of CGRP mAbs with other mAbs for comorbid diseases, such as psoriasis, multiple sclerosis, and autoimmune and neoplastic diseases. This evidence concerns the gene CALCA and neoplasm.